2024-10-01 - Analysis Report
## Merck & Co Inc (MRK) Stock Analysis Report

**Company Overview:** Merck & Co Inc is a global pharmaceutical company known for its research and development of innovative prescription medicines and vaccines.

**1. Performance Comparison:**

* **Cumulative Return:** 77.01% (MRK) vs. 133.28% (VOO) 
* **Relative Underperformance:** -56.27% (MRK) 
* **Relative Underperformance Rank:** 27.9% (indicating that MRK's underperformance is at the 27.9th percentile of its historical range)

**2. Recent Price Action:**

* **Closing Price:** $113.7 
* **5-day Moving Average:** $114.43
* **20-day Moving Average:** $116.26
* **60-day Moving Average:** $118.47

**3. Technical Indicators:**

* **RSI:** 42.09 (Neutral)
* **PPO:** -0.25 (Slight Bearish)
* **Delta_Previous_Relative_Divergence:** -10.17 (Short-term bearish)
* **Expected Return:** 0.0% (Max 5-year estimated return)

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-05 | 2.15 | 16.11 B$ |
| 2024-05-03 | 1.88 | 15.78 B$ |
| 2023-11-03 | 1.87 | 15.96 B$ |
| 2023-08-07 | -2.35 | 15.04 B$ |
| 2024-08-05 | -2.35 | 15.04 B$ |

The most recent earnings (2024-08-05) exceeded analyst estimates, with EPS coming in at $2.15 compared to an expected $1.97.  The revenue was also slightly above estimates, reaching $16.11 billion against an expected $15.98 billion. 

**5. News and Recent Issues:**

* **Recent Market Outlook:** MRK's stock has faced headwinds in recent months due to factors like competition in the pharmaceutical market, concerns regarding upcoming patent expirations for key products, and the overall uncertain economic landscape.
* **Analyst Opinions:** The majority of analysts still hold a "Buy" rating for MRK, citing its strong fundamentals and its ongoing efforts to develop new and innovative medicines.
* **Performance Highlights:**  MRK's strong revenue growth in recent quarters, driven by demand for key products like KEYTRUDA and GARDASIL, continues to be a positive factor. However, investors are closely monitoring the company's upcoming patent expirations and its potential impact on revenue.

**6. Overall Analysis:**

MRK is a large pharmaceutical company with a strong brand reputation and a diverse product portfolio. However, the company faces some challenges, including competition, upcoming patent expirations, and the potential impact of economic uncertainty.  While the recent earnings report showed positive results, the stock's underperformance compared to the S&P 500 suggests caution.  Its relative underperformance rank of 27.9% indicates that while MRK has underperformed, its performance is not dramatically out of line with its historical range. Technical indicators suggest a neutral to slightly bearish outlook. Overall, MRK remains a company worth watching, and investors should monitor its progress in new product development and its performance in key markets.

**7. Summary:**

MRK has lagged the S&P 500 in recent years, though it has shown signs of improvement in recent earnings. Its technical indicators suggest a neutral to bearish outlook.  While the company faces challenges, its strong fundamentals, commitment to innovation, and its current product portfolio remain attractive to investors. 
